Trial Profile
An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms BARRIER-P
- 10 Jan 2020 Status changed from active, no longer recruiting to completed.
- 19 Dec 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.
- 19 Dec 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.